The Novo, St. Jude and Kaiser Permanente-backed cardiac diagnostics technology developer floated above its range and closed its first day of trading 53% up on its IPO price.

Lilly Asia Ventures has returned for genetic testing startup Veritas Genetics' series B round, where it was joined by Jiangsu Simcere Pharmaceutical.

Sanofi's corporate venturing vehicle, Sanofi Genzyme BioVentures, joined investors including the Novartis and Qualcomm-founded DRx Capital for the round.

The Baxalta and GlaxoSmithKline-backed rare disease drug developer has now raised more than $140m since it was spun out of iPierian in 2013.

Lilly Asia Ventures has returned for genetic testing startup Veritas Genetics' series B round, where it was joined by Jiangsu Simcere Pharmaceutical.

Bayer invested $35m in the Switzerland-based gene editing company but it floated below its range and lowered the number of shares in the offering.

Pain assessment technology developer ePat is set to list on the Australian Stock Exchange today, providing an exit to Curtin University.

Ovia Health, the parenting and pregnancy app developer, has rebranded from Ovuline and secured $10m from investors including Blue Cross Blue Shield of Massachusetts.